Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2005)
27 slides from Starpharma's shareholder meeting presentation, Nov 16, 2005
Slide 1: Starpharma Holdings Limited Annual General Meeting
Starpharma Holdings Limited Annual General Meeting 16 November 2005
Slide 2: Chairman's Address
@ starp harma Chairman’s Address Peter Bartels Chairman
Slide 3: Chairman's Address
@ starpharma Chairman's Address Annual General Meeting of Starpharma Holdings Limited Wednesday 16 November 2005 As | prepare to present my third Chairman's address for Starpharma, there is a buzz of excitement among senior management and increasingly much improved sentiment in the biotechnology sec
Slide 4: Chairman's Address (continued): capital raising and board
Pharmaceuticals Partnerships Program which Federal Minister lan Macfarlane chose to announce during a visit to Starpharma’s operation in Melbourne. This grant is worth up to $5.6 million over 4 years. Capital raising Two day’s ago on Monday we announced that we had raised $12 million through a Share
Slide 5: Starpharma: Positioned for Success
@ starp harma Starpharma: Positioned for Success John Raff Chief Executive Officer
Slide 6: 2004 / 2005: The Year in Review
2004 / 2005: The Year in Review stsipharma ee Gales = § $US5.4M NIH funding for ComboGel™ December Phase | VivaGel™ trial — Forbes/Wolfe “Top 5 Nanotech breakthroughs of 2004” January Dow : Entire dendrimer portfolio to DNT for 30% share of DNT equity February Signed development deal with Anadis Ltd
Slide 7: Starpharma: Positioned for Success
Starpharma: Positioned for Success stsipharma Financially secure Non-dilutive, external funding for VivaGel™ in place VivaGel™ Phase | trial successful; further human trials scheduled and funded Dendrimer platform yielding multiple commercial opportunities Exceptional uptake of US ADRs Valuable equi
Slide 8: Share Placement and SPP
Share Placement and SPP stsipharma Two-Part Placement » Offer of 23.5m shares to raise $12 million = Issue price of $0.51 = 9.6m shares ($4.9m) immediately under 15% rule » 13.9m shares ($7.1m) subject to shareholder approval Use of Funds Product Pipeline Development DNT Collaborative Activities Ove
Slide 9: Indicative Timetable
Indicative Timetable stsipharma Announce A$15M Placement and SPP 14 November Settlement of first tranche of Placement shares 17 November Placement shares listed on ASX 18 November Record date for SPP 18 November SPP offer opens 21 November Closing Date for SPP 15 December Shareholder meeting to appr
Slide 10: Starpharma's Projects
@ starpharma Starpharma’s Projects starpharma
Slide 11: Starpharma's Pipeline
@ Starpharma’s Pipeline starpharma VivaGel™ ~ HIV —$—$—— > VivaGel™ - Herpes ——<—<—$ ‘ComboGel’ ————— Condom Coating ——$—_—______........ Device (TBC) ADME’ Engineering msn nnn Anti-Cancer Agent es oe Respiratory soncomamanenncn Anti-angiogenesis seen cee Anti-Cancer Diagnostic — GPCR Agonists eee >
Slide 12: DNT is a Valuable and Strategic Asset
DNT is a Valuable and Strategic Asset stsipharma SPL has a 33% holding in a private US company Dendritic Nanotechnologies Inc (DNT) DNT is a valuable, but as yet not externally priced, company ~ Existing revenue streams from deals with leading pharmaceutical and biotechnology companies including Pfi
Slide 13: VivaGel: A compelling commercial opportunity
@ starpharma VivaGel™ : A compelling commercial opportunity Jackie Fairley Chief Operating Officer 41
Slide 14: VivaGel — Lead Product for Prevention of STIs
VivaGel™ — Lead Product for Prevention of STIs stsipharma VivaGel™ packaged into pre-filled applicators. x VivaGel™ is a microbicide being developed to prevent sexually transmitted infections (STIs) in women « VivaGel™ is a gel-based formulation with a nanotech active, delivered privately via an app
Slide 15: HIV — A Preventable, Life Threatening Disease
HIV — A Preventable, Life Threatening Disease stsipharas » Human Immunodeficiency Virus (HIV) is the virus that causes AIDS (Acquired Immune Deficiency Syndrome) « AIDS is the most serious stage of the HIV infection, it results from the destruction of the infected person’s immune system * No cure fo
Slide 16: Microbicide Development Act 2005: US Senate
Microbicide Development Act 2005: US Senate stsipharma = The Microbicide Development Act 2005 introduced by H Clinton et al. Microbicides: a key STl prevention strategy well supported in the USA 44
Slide 17: SPL Awarded US$20.3m Funding from the NIH
@ SPL Awarded US$20.3m Funding from the NIH starpharma A$26m+ of non- dilutive funding Strong Endorsement of VivaGell™ Significantly de-risks’ VivaGel’™ Funding is provided without any downstream commercial obligations on future revenues generated from VivaGel™ Funding will allow Starpharma to take
Slide 18: Genital Herpes — Large and Growing Market
Genital Herpes — Large and Growing Market stsipharas « 22% of the US adult population has genital herpes; Est. cost (US) >$1.5B pa « Without intervention the prevalence of genital herpes in the US is expected to increase to 39% of men and 49% of women by 2025 Prevalence of Genital Herpes Europe: 10
Slide 19: Genital Herpes — Nasty, Incurable Disease
Genital Herpes — Nasty, Incurable Disease stsipharma = Infection is life-long, drugs do not cure = Results in painful blisters/uicers - Ulcers last 3-4 weeks; 4-5 ulcerative episodes p.a x Frequently causes anxiety and depression in affected - individuals = Increases affected individuals’ risk of HI
Slide 20: VivaGel — Exciting Product Showing Excellent Results
VivaGel™ — Exciting Product Showing Excellent Results starphama Product Offers Several Key Advantages Excellent Clinical Results in Human and Primate Trials Excellent Drug Characteristics Gel applications have significantly better take-up than condoms Female controlled, discreet and convenient Compe
Slide 21: Developed Countries: Market opportunity for microbicides
Developed Countries: Market opportunity for microbicides stsipharma Average Frequency of Use per Annum Market Penetration » Key assumptions — 291m women of reproductive age (15-49) in developed countries ~ Unit sale price circa US$2 ~ Usage rates according to published data 18
Slide 22: VivaGel — Excellent Market Opportunities
VivaGel™ — Excellent Market Opportunities @ starpharma x Starpharma is currently focused on four commercial applications of VivaGel™ Est. Market Size Est. Market Entry F TM VivaGel™ VivaGel ; . Premium : . Genital Herpes ‘ComboGel HIV Prevention " Condoms Prevention ET Combination Topical Microbicid
Slide 23: Starpharma: Value Highlights
@ Starpharma: Value Highlights starpharma Strong financial position NIH Funding Expected News flow Market opportunities Valuable Assets Successful institutional placement raised $12M (>2 years cash) US$20.3m of non-diluting funding Significant validation of the technology Funding de-risks developmen
Slide 24: Starpharma Holdings Limited
Starpharma Holdings Limited
Slide 25: Appendices
@ starpharma Appendices starpharma 23
Slide 26: Discovery Projects Overview
@ Discovery Projects Overview starpharma ADME Engineering™ ~ Use of dendrimers to improve pharmacokinetics and safety of existing small molecule drugs and protein therapeutics - Potential as patent extension mechanism, improved dose efficiency » Anticancer Agent - Specific example of ADME engineerin
Slide 27: VivaGel — Significant Advantages Over Competitors
VivaGel™ — Significant Advantages Over Competitors starphama Competitor Products Key Disadvantages MivaGel™ Advantages Significant Advantages over Other Products in Development* “As demonstrated by NIH selecting VivaGel™ Acidity Control _ (buffering agents) | initant 25
Starpharma Holdings — Shareholder Meeting (November 2005) on 6ix